The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLC
Francesco Guerrera, MD, University of Turin, Turin, Italy, discusses a meta-analysis evaluating adherence and surgical outcomes in patients with resectable non-small-cell lung cancer (NSCLC) receiving neoadjuvant immunotherapy with or without standard chemotherapy. Despite 13% of patients in the analysis not undergoing surgery, the findings suggest that neoadjuvant immunotherapy has an acceptable adherence rate and promising surgical outcomes, though further optimization of protocol duration and dosing could enhance results. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
